<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="http://medicalxpress.com/tmpl/default/css/default/feedRSS.xsl"?>
<rss version="2.0" 
	xmlns:media="http://search.yahoo.com/mrss/">
<channel>
<title>Medical Xpress: PHYSorg news tagged with: myopathy</title>
<link>http://medicalxpress.com/</link>
<language>en-us</language> 
<description>Medical Xpress internet news portal provides the latest news on Health and Medicine.</description>

 <item>
     <title>Uncleaned cells mean weak muscles</title>
   	 <description>The protein complex mTORC1 promotes muscle growth. However, should this complex remain constantly active, it impairs the ability of the cells to self-clean, causing myopathy. Scientists working with Markus Rüegg, Professor at the Biozentrum, University of Basel, describe the exact mechanism involved in the current issue of the scientific journal Cell Metabolism.</description>
     <link>http://medicalxpress.com/news/2013-04-uncleaned-cells-weak-muscles.html</link>
	 <category>Medical research</category>
	 <pubDate>Tue, 23 Apr 2013 10:14:46 EST</pubDate>
	 <guid isPermaLink="false">news285930880</guid>
	 <media:thumbnail url="http://s.ph-cdn.com/newman/gfx/news/tmb/2013/uncleanedcel.jpg" width="90" height="90" />
</item>
<item>
     <title>Vitamin D deficiency may contribute to alcohol-related muscular weakness</title>
   	 <description>Myopathy refers to a muscular disease in which muscle fibers do not function, resulting in muscular weakness and wasting. Vitamin D deficiency is a well-recognized cause of myopathy, and excessive drinking is often associated with low or subnormal levels of vitamin D. A review of studies of the relationship between alcohol-related myopathy and vitamin D deficiency indicates that vitamin D deficiency might partly explain the occurrence of the frequently observed myopathy in chronic alcoholism.</description>
     <link>http://medicalxpress.com/news/2012-12-vitamin-d-deficiency-contribute-alcohol-related.html</link>
	 <category>Addiction</category>
	 <pubDate>Fri, 14 Dec 2012 16:00:16 EST</pubDate>
	 <guid isPermaLink="false">news274696452</guid>
	 
</item>
<item>
     <title>New research model to aid search for degenerative disease cures</title>
   	 <description>(Medical Xpress)—Efforts to treat disorders like Lou Gehrig's disease, Paget's disease, inclusion body myopathy and dementia will receive a considerable boost from a new research model created by UC Irvine scientists.</description>
     <link>http://medicalxpress.com/news/2012-10-aid-degenerative-disease.html</link>
	 <category>Medical research</category>
	 <pubDate>Tue, 02 Oct 2012 13:13:22 EST</pubDate>
	 <guid isPermaLink="false">news268402331</guid>
	 
</item>
<item>
     <title>Researchers find new gene mutation associated with congenital myopathy</title>
   	 <description>University of Michigan researchers have discovered a new cause of congenital myopathy: a mutation in a previously uncharacterized gene, according to research published this month in the American Journal of Human Genetics.</description>
     <link>http://medicalxpress.com/news/2012-07-gene-mutation-congenital-myopathy.html</link>
	 <category>Genetics</category>
	 <pubDate>Wed, 25 Jul 2012 16:52:27 EST</pubDate>
	 <guid isPermaLink="false">news262453933</guid>
	 
</item>
<item>
     <title>Etanercept shows promise for treating dermatomyositis</title>
   	 <description>A multicenter pilot study of etanercept for treatment of dermatomyositis found no major safety concerns and many patients treated with the drug were successfully weaned from steroid therapy. These results are encouraging, but larger studies are needed to further investigate the safety and efficacy of etanercept. Results of this clinical trial are available in Annals of Neurology, a journal published by Wiley-Blackwell on behalf of the American Neurological Association.</description>
     <link>http://medicalxpress.com/news/2011-06-etanercept-dermatomyositis.html</link>
	 <category>Neuroscience</category>
	 <pubDate>Fri, 17 Jun 2011 03:53:54 EST</pubDate>
	 <guid isPermaLink="false">news227501620</guid>
	 
</item>
<item>
     <title>FDA announces new limits on high-dose simvastatin (Zocor)</title>
   	 <description>The United States Food and Drug Administration (FDA) today announced new limitations to the use of high-dose simvastatin, due to the increased risk of muscle pain and weakness (myopathy) and in rare cases, kidney damage and failure.</description>
     <link>http://medicalxpress.com/news/2011-06-fda-limits-high-dose-simvastatin-zocor.html</link>
	 <category>Cardiology</category>
	 <pubDate>Thu, 09 Jun 2011 11:42:39 EST</pubDate>
	 <guid isPermaLink="false">news226838536</guid>
	 
</item>


</channel>
</rss>
